Mylan Chairman Robert Coury On Lipitor's Future and India/Japan Expansion: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Mylan Inc. CEO Robert J. Coury demonstrated his ability to be a trendsetter when Mylan acquired Matrix Laboratories in 2007 at the highest value - at the time - for an India pharmaceutical company. Though doubted for that move and the next - of buying Merck KGaA's generics business for $6.8 billion, Coury now boasts of establishing a global generics footprint with a one-of-a-kind vertically integrated platform to build maximum operational efficiencies.
You may also be interested in...
Mylan Weighs "Big Bang Or Phased" Products Rollout In India; Significant Workforce Additions Planned
MUMBAI - On a trip to India, Mylan Inc. CEO and Chairman Robert Coury praised the "voluminous contributions" of Indian arm Matrix Laboratories Ltd. in Mylan's global-scale vertical integration drive, but also announced that the company would rebrand Matrix as Mylan as it moves forward with launching Mylan products in India
Teva Pharmaceutical Industries Ltd. announced May 16 that it is acquiring more than half of Japan's third largest generic drugmaker and extending an offer to purchase the remaining portion of the company
Apotex’s announcement that FDA is lifting an import alert on products manufactured at two Canadian facilities could be interpreted as a good sign for the near-term availability of Lipitor generics, either from first-filer Ranbaxy Laboratories Ltd. or subsequent ANDA filers.